BioNTech enters settlement with US agency, UPenn over COVID vaccine royalties

BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University of Pennyslvania over the payment of royalties related to its COVID-19 vaccine, the company said in filings on Friday.

Sign up for Reuters newsletters Reuters Business Reuters Business

BioNTech enters settlement with US agency, UPenn over COVID vaccine royalties

Embraer sells two C-390 military aircraft to undisclosed client

Taiwan's science ministry warns spending cuts could hit chips, AI funding

UnitedHealth, Amedisys extend deadline to close $3.3 billion deal

Shell shuts down oil processing unit to investigate leak, Singapore's port authority says

Ark's Cathie Wood calls for tax clarity as she rides 'Trump bump'

Wall St Week Ahead Trump's first actions and job data to test market in January

Osamu Suzuki, who led Japanese automaker into India, dies at 94

Wall St futures ease as strong holiday-shortened week draws to a close

US equity funds receive big inflows on cool inflation, funding bill, and holiday rally

Sponsors are not involved in the creation of newsletters or other Reuters news content. Advertise in this newsletter or on Reuters.com Reuters Business is sent every weekday. Think your friend or colleague should know about us? Forward this newsletter to them. They can also sign up here. Want to stop receiving this email? Unsubscribe here. To manage which newsletters you're signed up for, click here. Terms & Conditions and Privacy Statement

© 2024 Thomson Reuters. All rights reserved. 3 Times Square, New York, NY 10036